louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04781751: Ultrasonographic Insulin Versus Dexamethasone Injection With Local Anestheticss in Diabetic Patients With Mild to Moderate Median Nerve Entrapement Neuropathy .
Official title: Ultrasonographic Insulin Versus Dexamethasone Injection With Local Anestheticss in Diabetic Patients With Mild to Moderate Median Nerve Entrapement Neuropathy .
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Pain, Neuropathic
Lead sponsor: Minia University
Sponsor class: OTHER
First posted: 2021-03-04
Enrollment: 150
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Insulin injection in carpal tunnel compared with dexamethsone in diabetic patients

Detailed description: Trial to decrease median nerve entrapement neuropathy recurrence using insulin co-injection

Eligibility criteria: Inclusion Criteria:

* All diabetic patients with carpal tunnel syndrome

Exclusion Criteria:

* Refusal to participate

Primary outcomes:
measure: pain relief
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: ALMinya
country: Egypt
facility: Minia University
Study officials:
References:
Clinical trial NCT04507451: Respiratory Muscle Training in ICU Patients
Official title: Inspiratory and Expiratory Muscle Training in Critically Ill Patients Weaned From Mechanical Ventilation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Critical Illness
Inspiratory Muscle Strength
Mechanical Ventilation
Respiratory Muscle Training
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2020-08-11
Enrollment: 100
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Respiratory muscle weakness is common after mechanical ventilation and occurs early. This can limit functional recovery. Respiratory muscle training is often neglected in clinical practice. Some data indicates that inspiratory muscle training increases inspiratory muscle strength and quality of life. The aim of the study is to assess the impact of combined inspiratory and expiratory muscle training on inspiratory muscle strength. The second aim is to assess the impact of this training program on expiratory muscle strength.


Eligibility criteria: Inclusion Criteria:

* patient from mechanical ventilation after at least 24 hours of support
* collaborative patient

Exclusion Criteria:

* confusion, mental disorder
* not french speaking
* pulmonary surgery in the past 12 months
* external ventricular drain
* previous pneumothorax or pneumothorax not drained
* rib fractures
* alveolar hemorrhage
* hemodynamic instability
* labial occlusion impossible (face burn, facial paralysis)
* patient refusal

Primary outcomes:
measure: change in inspiratory muscle strength
timeFrame: between 7 to 15 days after ICU discharge (compared to ICU discharge)
measure: change in inspiratory muscle strength
timeFrame: 1 month after ICU discharge (compared to ICU discharge)
Secondary outcomes:
measure: change in expiratory muscle strength
timeFrame: between 7 to 15 days after ICU discharge (compared to ICU discharge)
measure: change in expiratory muscle strength
timeFrame: 1 month after ICU discharge (compared to ICU discharge)
measure: respiratory infections
timeFrame: 1 month after ICU discharge
measure: change in dyspnea perception
timeFrame: 1 month after ICU discharge (compared to hospital discharge)
measure: impact of dyspnea on physical activities
timeFrame: between 7 to 15 days after ICU discharge
measure: impact of dyspnea on physical activities
timeFrame: 1 month after ICU discharge
Other outcomes:
Locations:
city: Liège
country: Belgium
facility: University Hospital of Liège
Study officials:
References:
Clinical trial NCT04300751: Alcohol and Opioids
Official title: Interactions of Alcohol and Opioids: Pharmacodynamic Effects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Opioid Use
Alcohol Drinking
Keywords: opioid
opiate
alcohol
Lead sponsor: University of Kentucky
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2020-03-09
Enrollment: 10
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This study will examine the effects of doses of alcohol/placebo and doses of opioid/placebo, alone and in combination. The primary outcomes are related to pharmacodynamic measures (subjective ratings of drug liking and other abuse-related effects; physiological outcomes) to determine the interaction effects of these compounds.


Eligibility criteria: Inclusion Criteria:

* Healthy adults ages 21-55
* Current non-medical use of opioids
* Previous alcohol use

Exclusion Criteria:

* Physical dependence on opioids, alcohol, or benzodiazepines/sedative/hypnotics
* Seeking treatment for drug use
* Significant medical problems

Primary outcomes:
measure: Change in Subject-Rated Outcomes
timeFrame: These outcomes (visual analog scores, scale of 0-100) will be recorded prior to and in regular intervals after drug administration for the duration of the session (approx. 6.5 hours per session)
Secondary outcomes:
measure: Change in Oxygen Saturation
timeFrame: Oxygen saturation will be recorded prior to and in regular intervals after drug administration for the duration of the session (approx. 6.5 hours per session)
measure: Change in Respiration Rate
timeFrame: Respiration rate will be recorded prior to and in regular intervals after drug administration for the duration of the session (approx. 6.5 hours per session)
measure: Change in Blood pressure
timeFrame: Blood pressure will be recorded prior to and in regular intervals after drug administration for the duration of the session (approx. 6.5 hours per session)
Other outcomes:
Locations:
city: Lexington
country: United States
facility: University of Kentucky
state: Kentucky
Study officials:
affiliation: University of Kentucky
name: Sharon Walsh, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03127254: Can Making Video Narratives Benefit Adolescents With Cancer
Official title: Can Making Video Narratives Benefit Adolescents With Cancer
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Pediatric Cancer
Keywords: Video Narrative
Lead sponsor: Case Comprehensive Cancer Center
Sponsor class: OTHER
Collaborators: name: MetroHealth Medical Center
name: Palo Alto University
First posted: 2017-04-25
Enrollment: 0
Sex: ALL
Minimum age (years): 11
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to learn more about the content of and benefits of making video testimonials in adolescents with cancer.

Detailed description: The current research aims to:

A. enlist teens with cancer to produce video narratives about their experiences with their illness B. explicitly characterize and investigate the videos' content and C. determine what aspects of the production were helpful to the teen making them and predicted to be helpful to those watching them.

Eligibility criteria: Inclusion Criteria:

* Diagnosed with cancer
* Patients receiving cancer treatment for the first time
* Can complete study before high school graduation
* Must be able to read and understand English

Exclusion Criteria:

* Participants cannot have been treated for other chronic illnesses prior to cancer diagnosis
* Patients with cognitive and.or verbal capacities impaired to the point where they cannot consent or assent for themselves
* Patients who cannot communicate narratives clearly due to cognitive and/or verbal impairments

Primary outcomes:
measure: linear regression of pediatric quality of life (PedsQL), TIPI, and coded themes from video narratives on coherence, subjectivity and redemption
timeFrame: at end of intervention - Approximately 60 minutes after enrolling on study
Secondary outcomes:
measure: linear regression of coded resilient qualities of narrative with Post Video Impression Questionnaire
timeFrame: at end of intervention - Approximately 60 minutes after enrolling on study
measure: linear regression of impact experienced from making the video narrative with summed scores of participants willingness to post online
timeFrame: at end of intervention - Approximately 60 minutes after enrolling on study
measure: linear regression of perceived impact with summed scores of participants willingness to post the video online
timeFrame: at end of intervention - Approximately 60 minutes after enrolling on study
Other outcomes:
Locations:
Study officials:
affiliation: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center
name: Jennifer C Anderson, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00212654: Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan
Official title: Controlled Study of ONO-1101 in Patients With Postoperative Tachyarrhythmias in Japan
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Postoperative Supraventricular Tachyarrythmia
Keywords: ONO-1101
Landiolol Hydrochloride
Postoperative
supraventricular tachyarrhythmia
Lead sponsor: Ono Pharmaceutical Co. Ltd
Sponsor class: INDUSTRY
First posted: 2005-09-21
Enrollment: 165
Sex: ALL
Minimum age (years): 21
Maximum age (years): 84
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy and safety of ONO-1101 in postoperative supraventricular tachyarrhythmias.


Eligibility criteria: Inclusion Criteria:

1. 20 years or older
2. Postoperative supraventricular tachyarrhythmias
3. Within 7 days postoperatively
4. Other inclusion criteria as specified in the protocol

Exclusion Criteria:

1. Acute myocardial infarction (within 1 month after onset)
2. Severe heart failure \[New York Heart Association (NYHA) functional class III or higher\]
3. Atrioventricular block (grade II or higher), or sick sinus syndrome
4. Other exclusion criteria as specified in the protocol

Primary outcomes:
measure: Percentage of patients who met the heart rate reduction criteria (20% reduction from the baseline heart rate and a heart rate of <100 beats/min)
Secondary outcomes:
measure: Heart rate, blood pressure, rate-pressure-product and ECG
Other outcomes:
Locations:
Study officials:
affiliation: Ono Pharmaceutical Co. Ltd
name: Project Leader, Development Planning
role: STUDY_DIRECTOR
References:
Clinical trial NCT00185354: FC Patch Comparator Study
Official title: Multi-center, Open, Randomized, Parallel Group Comparison of Cycle Control for Seven Cycles and Endometrial Safety in a Subgroup for Thirteen Cycles of Contraceptive Patch SH P00331F (0.9 mg Ethinylestradiol/1.9 mg Gestodene) vs. a Contraceptive Comparator Patch (0.6 mg Ethinylestradiol/6 mg Norelgestromin) in 400 Healthy Female Volunteers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Contraception
Keywords: FC patch
comparator study
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2005-09-16
Enrollment: 422
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to compare bleeding pattern and safety of contraceptive patch SH P00331F to a marketed comparator.

Detailed description: The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Eligibility criteria: Inclusion Criteria:

* Healthy female volunteer aged 18-35, smokers 18-30

Exclusion Criteria:

* Contraindications for using hormonal contraceptives

Primary outcomes:
measure: Bleeding pattern and cycle control
timeFrame: 13 cycles
measure: Number of pregnancies
timeFrame: 13 cycles
Secondary outcomes:
measure: Adverse events collection
timeFrame: 13 cycles
measure: Endometrial biopsy
timeFrame: 13 cycles
measure: Physical and gynecological exam
timeFrame: 13 cycles
Other outcomes:
Locations:
city: Wörgl
country: Austria
state: Tirol
city: Bregenz
country: Austria
city: Graz
country: Austria
city: Wien
country: Austria
city: Wien
country: Austria
city: Zeltweg
country: Austria
city: Helsinki
country: Finland
city: Helsinki
country: Finland
city: Turku
country: Finland
city: Turku
country: Finland
city: Biarritz
country: France
city: Bordeaux
country: France
city: COMPIEGNE cedex
country: France
city: Compiegne
country: France
city: Maisons lafitte
country: France
city: Montargis
country: France
city: Nancy Cedex
country: France
city: Pantin
country: France
city: Paris
country: France
city: Roanne
country: France
city: Saint Germain En Laye
country: France
city: Toulouse
country: France
city: San Fernando
country: Spain
state: Cádiz
city: Pontevedra
country: Spain
state: Galicia
city: Salt
country: Spain
state: Girona
city: Barcelona
country: Spain
city: Guadalajara
country: Spain
city: Santiago de Compostela
country: Spain
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT05278754: Independent Predictors Analysis and Model Construction of Cavitary Central Lung Cancer
Official title: Independent Predictors Analysis and Model Construction of Cavitary Central Lung Cancer: a Retrospective, Multicenter Trial
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Central Lung Cancer
Keywords: Central Lung Cancer
Cavity
Predictor
Lead sponsor: The Central Hospital of Lishui City
Sponsor class: OTHER
Collaborators: name: The First Affiliated Hospital of Soochow University
name: The Second Affiliated Hospital of Medical College of Zhejiang University
name: Affiliated Hospital of Xinjiang Medical University
First posted: 2022-03-14
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: This is a multicenter study. Patients from Lishui Central Hospital of Zhejiang Province, the Second Affiliated Hospital of Medical College of Zhejiang University, and Affiliated Hospital of Xinjiang Medical University who meet the above criteria will be included in this study

Brief summary: This study is a retrospective, multicenter clinical study. The main goal is to identify the risk factors for cavity formation in central-type lung cancer lesions, and to construct a prediction model for cavity formation in central-type lung cancer lesions based on the above risk factors.


Eligibility criteria: Inclusion Criteria:

1. Age：older than 18 years；
2. Clinical or pathologically confirmed central lung cancer;
3. Lesions without cavities at first diagnosis of central lung cancer;
4. Performed complete laboratory and imaging research at the first diagnosis of the central lung cancer;
5. Patients with cavities formation during follow up, and the cavities were independently confirmed by at least 3 imaging experts;
6. Patients with complete medical records;

Exclusion Criteria:

1. Patients suffering other malignant tumors;
2. Patients missing the imaging data;
3. Patients missing the clinical data.

Primary outcomes:
measure: Formation of cavities in the central lung cancer, assessed up to 18 months.
timeFrame: Time from enrollment to the time of cavities formation, assessed up to 18 months.
Secondary outcomes:
measure: Hemoptysis in patients with central lung cancer, assessed up to 18 months.
timeFrame: Time from enrollment to hemoptysis, assessed up to 18 months.
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02955654: Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder
Official title: Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Obsessive-Compulsive Disorder
Lead sponsor: Shanghai Mental Health Center
Sponsor class: OTHER
First posted: 2016-11-04
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether acceptance and commitment therapy is effective in the treatment of SSRIs-resistant obsessive- compulsive disorder.

Detailed description: The patients who were SSRI-resistant will be randomized to ACT, aripiprazole, or SMT. Independent evaluators, blind to treatment,will evaluate patients during the study.The Yale-Brown Obsessive Compulsive Scale (YBOCS)will be used to measure OCD severity.

Eligibility criteria: Inclusion Criteria:

1. age between 18 and 65;
2. no less than 9 years in education;
3. a DSM-IV diagnosis of OCD
4. moderately symptomatic (Yale-Brown Obsessive Compulsive Scale score≥16)
5. received at least two kinds of SSRIs at optimal dose for more than 12 weeks An optimal dose is described as following: clomipramine hydrochloride, at least 225 mg/d;fluoxetine, at least 60 mg/d; paroxetine hydrochloride, at least 60 mg/d; sertraline hydrochloride, at least 200 mg/d; fluvoxamine, at least 250 mg/d; citalopram hydrobromide,at least 60 mg/d; and escitalopram oxalate, at least 40 mg/d.Patients who are unable to tolerate the supposed optimal doses were also eligible if at their maximally tolerated dose.

Exclusion Criteria:

1. with comorbid Axis I psychiatric disorders
2. drug abuse in the last 3 months
3. HAMD\>25
4. too severe to receive ACT or evaluation
5. at high risk of suicide
6. pregnant or prepare for pregnancy
7. with somatic disorder
8. received aripiprazole(≥10mg for 8weeks) or ACT(8 times within 2 months) before
9. treated with no more than one kind of SSRI before

Primary outcomes:
measure: Yale Brown Obsessive Compulsive Scale
timeFrame: 0,8week
Secondary outcomes:
measure: Beck Depression Inventory
timeFrame: 0,8week
measure: Acceptance and Action Questionnaire
timeFrame: 0,8week
measure: Treatment Evaluation Inventory-Short Form
timeFrame: 0,8week
measure: Basic life sign
timeFrame: 0,8week
measure: BMI
timeFrame: 0,8week
measure: Abnormal Involuntary Movement Scale
timeFrame: 0,8week
Other outcomes:
Locations:
Study officials:
affiliation: Shanghai Mental Health Center
name: Zhen Wang, Ph.D M.D
role: STUDY_DIRECTOR
References:
Clinical trial NCT00551954: Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Type 2 Diabetes
Lead sponsor: Technische Universität Dresden
Sponsor class: OTHER
First posted: 2007-11-01
Sex: ALL
Minimum age (years): 35
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Endothelial dysfunction (ED) has been suggested as a possible causal link between postprandial hyperglycemia and cardiovascular events in patients with type 2 diabetes. Recent trials demonstrated a reduction of cardiovascular events by treatment with the alpha glucosidase inhibitor acarbose - a drug which mainly reduces postprandial glucose excursions. We were interested whether patients with newly diagnosed type 2 diabetes showed postprandial ED and if so whether acarbose was able to improve this condition.


Eligibility criteria: Inclusion Criteria:

* age 35-75 years
* type 2 diabetes (newly diagnosed)
* well glycemic control (HbA1c \</= 8.1)
* leucocyte count \> 6.2 or hs CrP \> 1

Exclusion Criteria:

* hs CrP \> 10
* type 1 diabetes
* previous treatment with antidiabetic drugs

Primary outcomes:
measure: forearm blood flow assessed by forearm occlusion plethysmography after a mixed meal
timeFrame: at baseline and after 20 weeks of treatment
Secondary outcomes:
measure: forearm blood flow assessed by forearm occlusion plethysmography in the fasting state, plasma glucose excursion in response to the mixed meal, insulin levels in response to the mixed meal, triglyceride levels in response to the mixed meal
timeFrame: at baseline and after 20 weeks of treatment
Other outcomes:
Locations:
Study officials:
affiliation: Center for Clinical Studies, Fiedlerstr. 34, 01307 Dresden, Germany
name: Markolf Hanefeld, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05823454: Consciousness-specific Brain Network Connection of Propofol Sedation and Prolonged Disorders of Consciousness
Official title: Consciousness-specific Brain Network Connection of Propofol Sedation and Prolonged Disorders of Consciousness Based on Electroencephalogram and Event-related Potential
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Consciousness Disorder
Keywords: Prolonged Disorders of Consciousness
Propofol
Brain Functional connectivity
Electroencephalography
Lead sponsor: Beijing Tiantan Hospital
Sponsor class: OTHER
First posted: 2023-04-21
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with chronic disorders of consciousness

Brief summary: Consciousness-specific Brain Network Connection of Propofol Sedation and Prolonged Disorders of Consciousness based on Electroencephalography and Auditory Event-related Potentials


Eligibility criteria: Inclusion Criteria:

* Age 18 - 65 years old, native Chinese speaker, dextromanuality;
* Chronic disorder of consciousness;
* Spinal cord electrical stimulator implantation under general anesthesia;
* Signed informed consent.

Exclusion Criteria:

* Continuous sedation was administered within 72 hours prior to the study;
* Open head injury, parenchymatectomy and other damage of brain structural integrity;
* The intracranial compliance decreased due to hydrocephalus and swelling;
* Known hearing impairment;
* Airway stenosis and various causes of severe ventilation or ventilation dysfunction;
* Known or suspected cardiac dysfunction;
* Allergic to intravenous general anesthetics;
* Associated with other mental or neurological diseases;
* Other reasons are not suitable to participate in this study.

Primary outcomes:
measure: EEG Spectral Characteristics
timeFrame: During the trial(up to 3 hours for each subject)
Secondary outcomes:
measure: Cortical Connectivity
timeFrame: During the trial(up to 3 hours for each subject)
measure: Derived quantitative indicators
timeFrame: During the trial(up to 3 hours for each subject)
measure: Characteristics of sleep
timeFrame: During the trial(up to 24 hours for each subject)
measure: Dynamic Patterns of Cortical Connectivity
timeFrame: During the trial(up to 3 hours for each subject)
measure: Rate of patients recovered consciousness after surgery
timeFrame: During the trial(through study completion, 180 days)
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing Tiantan Hospital, Capital Medical University
Study officials:
References: